FDA halts trials of Bellicum’s cancer drug

Jan 31, 2018

Bellicum Pharmaceuticals has suffered a setback with its trials of an experimental cancer drug.

Earlier this week the Houston-based biotech firm announced that the FDA has placed a clinical hold on four U.S. studies of BPX-501, a new cellular immunotherapy for cancer and orphan inherited blood disorders. The agency made the move after three patients in the studies developed brain disorder, possibly related to the treatment.

Bellicum reported that there could be several factors affecting the cases, and that it’s working with the FDA to resolve the issues.  

Read the full report. 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments